Search for dissertations about: "chemotherapy drug"

Showing result 1 - 5 of 143 swedish dissertations containing the words chemotherapy drug.

  2. 1. Managing chemotherapy risks : Learning from medication errors and developing a national knowledge source for chemotherapy regimens

    Author : Ann-Sofie Fyhr; Ergonomi och aerosolteknologi; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; SAMHÄLLSVETENSKAP; SOCIAL SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; SAMHÄLLSVETENSKAP; MEDICAL AND HEALTH SCIENCES; SOCIAL SCIENCES; Chemotherapy; Chemotherapy regimens; Medication errors; Patient safety; e-library; Standardisation; User evaluation; Usability; Chemotherapy; Chemotherapy regimens; Medication errors; Patient safety; e-library; Standardisation; User evaluation; Usability;

    Abstract : The basics in cancer treatment are surgery, radiation therapy, and treatment with cancer drugs, often combined. Chemotherapy regimens that define the drugs used, the dosage, the frequency and duration of drug administration, have been developed and used for different cancer diagnoses. READ MORE

  4. 2. Biopharmaceutical Evaluation of Intra-arterial Drug-Delivery Systems for Liver Cancer : Investigations in healthy pigs and liver cancer patients

    Author : Elsa Lilienberg; Hans Lennernäs; Erik Sjögren; Niklas Axén; Helen M. Burt; Uppsala universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; in vivo release; drug delivery systems; local delivery; drug disposition; doxorubicin; hepatocellular carcinoma; transarterial chemoembolization; transarterial chemotherapy infusion; Pharmaceutical Science; Farmaceutisk vetenskap;

    Abstract : There are currently two types of intra-arterial drug-delivery system (DDS) in clinical use in the palliative treatment of primary liver cancer. The chemotherapeutic drug doxorubicin (DOX) can be formulated into a drug-in-lipiodol emulsion (LIPDOX) or a microparticulate drug-eluting bead system (DEBDOX). READ MORE

  5. 3. Optimisation of Chemotherapy Treatment in Advanced Colorectal Cancer

    Author : Åke Berglund; Ragnar Hultborn; Uppsala universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; Colorectal cancer; chemotherapy; 5-fluorouracil; dose-effect relationship; ex vivo assay; thymidylate synthase; p53; CEA; TPS; VEGF; bFGF.; Onkologi; Oncology; Onkologi; Oncology; onkologi;

    Abstract : Colorectal cancer is one of the most common malignant diseases in Sweden – more than 5000 new cases are diagnosed each year. The overall five-year survival is about 60% and in cases of recurrence the prognosis is poor. READ MORE

  6. 4. Risks in the chemotherapy process and possibilities for improvement

    Author : AnnSofie Fyhr; Ergonomi och aerosolteknologi; []
    Keywords : TEKNIK OCH TEKNOLOGIER; ENGINEERING AND TECHNOLOGY; TEKNIK OCH TEKNOLOGIER; ENGINEERING AND TECHNOLOGY; Medication errors; Cytotoxic drugs; Chemotherapy; Health care; Risk management; Improvements;

    Abstract : Medications are of considerable help if healthcare providers are able to administer them to patients safely and appropriately. The medication use process is complex and a team of professionals – doctors, nurses, and pharmacists – work together with the patient for optimal treatment effect. READ MORE

  7. 5. Individually Tailored Toxicity-based Chemotherapy : Studies on Patients with Primary and Metastatic Breast Cancer

    Author : Henrik Lindman; Jonas Bergh; Carl Blomqvist; Peter Nygren; Bo Nordenskjöld; Uppsala universitet; []
    Keywords : MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; breast cancer; tailored chemotherapy; toxicity-based dosing; high-dose therapy; MR imaging; G-CSF; epirubicin; docetaxel; cyclophosphamide; 5-fluorouracil; Onkologi; Oncology; Onkologi;

    Abstract : Standard dosing of chemotherapy based on body surface area (BSA) results in large individual differences in toxicity due to a large inter-patient variability in pharmacokinetics (PK) and pharmacodynamics (PD). This results in under-dosing in certain patients with a potentially weaker antitumoral effect. READ MORE